Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Details for Australian Patent Application No. 2002322527 (hide)

International Classifications

Event Publications

16 January 2003 Complete Application Filed

Priority application(s): 60/306,621 19.07.01 US

22 May 2003 Application Open to Public Inspection

Published as AU-B-2002322527

17 April 2008 Application Accepted

Published as AU-B-2002322527

14 August 2008 Standard Patent Sealed

25 September 2008 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 06 Aug 2008. Address for service in Australia - Freehills Patent & Trade Mark Attorneys Level 43 101 Collins Street Mebourne VIC 3000

15 October 2009 Amendment Made

The nature of the amendment is: Amend the patentee name from CV Therapeutics, Inc. to Gilead Palo Alto, Inc.

10 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.